

\$8.30M

Total Funding to Date



JAMES AMIHOOD

Founder and CEO

“The big vision is to take your mobile phone or smart speaker and for it to detect and monitor an array of different diseases.”

MISSION STATEMENT

Cardiokol develops voice-based markers and methods for easily monitoring and screening heart rhythm disorders in large at-risk populations.



@Cardiokol

HOW IT ALL STARTED

2017 - Founding Cardiokol

Cardiokol was founded to utilize proprietary technology to monitor heart health.

2019 - Seed Funding

Round lead by Kamet Ventures (ex AXA ventures arm), Cardiokol received \$3.3M

ACHIEVEMENTS

2021 - G4A Partnership

Cardiokol is selected as one of G4A's Growth Track Finalists

2022 - Commercializing

First product launched in Q2 of 2022

2022 - Groundbreaking Patent

US Patent Granted "Verbal Periodic Screening Heart Disease"

2022 - Award Winning

Cardiokol receives an award for being the 'Most Innovative Solution Oracle Startup Idol' from H+ Digital Health 2022 - InsurTech Hub Munich

WHAT'S NEXT?

Moving Forward

James Amihood has plans to expand Cardiokol's base of bio-markers for other chronic diseases.